CRISPR variant selectively targets tumor DNA
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Jun-2026 03:16 ET (23-Jun-2026 07:16 GMT/UTC)
A long-standing mystery in cancer treatment is how tumor cells so often become resistant to drugs, even ones they have never encountered before.
Duracyte is a biotechnology company developing implantable “living pharmacy” devices designed to continuously produce therapeutic proteins inside the body. The company plans to initiate a Phase 1 clinical trial this year evaluating patients with recurrent ovarian cancer. Duracyte is the third company launched by RBL LLC, following Sentinel BioTherapeutics and SteerBio, reinforcing Houston’s growing role as a biotechnology innovation hub.
Leucine-rich repeat-containing 8A (LRRC8A) is a ubiquitously expressed transmembrane protein that functions as the essential component of volume-regulated anion channels (VRACs). These channels are integral to maintaining osmotic balance, metabolite transport, and intercellular communication, thereby ensuring ion homeostasis and facilitating cellular responses to hypotonic stress, oxidative damage, and mechanical cues.
The Broad Institute’s Cancer Dependency Map Consortium (DMC) is an academic-industry collaboration that has transformed the study of cancer by developing one of the most comprehensive inventories of tumor vulnerabilities. The next stage of the academic-industrial partnership aims to expand beyond cancer vulnerabilities to investigate cancer resistance, surface targets, and high-dimensional readouts.